Enanta Pharmaceuticals, Inc. (ENTA) Stock Score, Valuation & Financial Research
Enanta Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 13/100.
Quick answer for ENTA
Enanta Pharmaceuticals, Inc. currently has a Wall Street Score of 13/100. The stored market price is $13.12. Its financial score is 25/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Enanta Pharmaceuticals, Inc. does
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
ENTA financial snapshot
- Wall Street Score:
- 13/100
- Current price:
- $13.12
- Market capitalization:
- $381.5M
- Revenue:
- $65.3M
- Net income:
- $-63.2M
- Free cash flow:
- $-32.2M
- Cash:
- $33.4M
- Total debt:
- $55.7M
- EPS:
- -2.41
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 2/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $-32.2M, showing cash burn in the current stored period.
- The balance sheet shows $33.4M of cash versus $55.7M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-07.
How to research ENTA
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.